Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 6/20 | 0.62 |
| ▸ | CNR1 | P21554 | 4/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | CREBBP | Q92793 | 3/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | PLK1 | P53350 | 1/20 | 0.52 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.52 |
| ▸ | HTR7 | P34969 | 2/20 | 0.51 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5418358 | 0.89 | SMN1; SMN2 (0.59) | CNR2CNR1SMN1; SMN2ALDH1A1CREBBP | |
| SCHEMBL9540544 | 0.88 | PLK1 (0.66) | CNR2CNR1SMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL5454647 | 0.88 | CNR2 (0.74) | CNR2CNR1SMN1; SMN2ALDH1A1CREBBP | |
| SCHEMBL5455063 | 0.87 | CNR2 (0.53) | CNR2CNR1SMN1; SMN2ALDH1A1CREBBP | |
| SCHEMBL14463824 | 0.86 | CNR2 (0.57) | CNR2CNR1SMN1; SMN2ALDH1A1CREBBP | |
| SCHEMBL9344335 | 0.86 | PLK1 (0.66) | CNR2CNR1ALDH1A1KMT2APLK1 | |
| SCHEMBL5454706 | 0.85 | DRD3 (0.60) | CNR2CNR1SMN1; SMN2ALDH1A1CREBBP | |
| SCHEMBL5453696 | 0.85 | SMN1; SMN2 (0.62) | CNR2CNR1SMN1; SMN2ALDH1A1CREBBP | |
| SCHEMBL5451254 | 0.84 | SMN1; SMN2 (0.61) | CNR2CNR1SMN1; SMN2ALDH1A1CREBBP | |
| SCHEMBL5448205 | 0.83 | SMN1; SMN2 (0.54) | CNR2CNR1SMN1; SMN2ALDH1A1CREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | ACADIA PHARMACEUTICALS INC. (US) | 2007-09-13 | — | — | US | disclosed |
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | ACADIA PHARMACEUTICALS INC. (US) | 2007-09-13 | — | — | US | disclosed |
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | ACADIA PHARMACEUTICALS INC. (US) | 2007-09-13 | — | — | US | disclosed |
| WO-2007079239-A2 | BICYCLIC NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | ACADIA PHARMACEUTICALS INC. (US) | 2007-07-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | GIPR, GHSR, GHRHR | CNR2 106/4885CNR1 65/4885SMN1; SMN2 1701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.